



**Prof. Vita Dolžan, MD, PhD**

Pharmacogenetics Laboratory  
Institute of Biochemistry  
Faculty of Medicine  
University of Ljubljana  
Slovenia

Prof. Dolžan is a Full Professor of Biochemistry and Molecular Biology and the founder and Head of the Pharmacogenetics Laboratory at the Institute of Biochemistry, Faculty of Medicine, University of Ljubljana. She has vast research experience in the field of pharmacogenetics and implementation of novel molecular biology based methods into clinical use. She published over 70 SCI indexed papers that have over 2000 citations. She investigates the influence of genetic variability in drug metabolizing enzymes, transporters and drug targets on drug treatment response in cancer, anticoagulant, antidiabetic, antipsychotic, antidepressant, antirheumatic, and antiepileptic drug treatment. She is particularly interested in development of clinical pharmacogenetic models that would facilitate the translation of personalized medicine into clinical practice. She also works on the promotion of pharmacogenomics knowledge and awareness among Slovenian medical professionals and general public. In 2013 she received Lapanje award from the Slovenian Biochemical Society as a professional recognition of outstanding contribution to the development of biochemical science in Slovenian and international arena and for the successful transfer of scientific research findings into clinical practice.

**Selected references:**

1. Terzić T, Kastelic M, Dolžan V, Plesničar BK. Genetic variability testing of neurodevelopmental genes in schizophrenic patients. *J Mol Neurosci* 2015;56(1):205-11.
2. Goričar K, Kovač V, Jazbec J, Zakotnik B, Lamovec J, Dolžan V. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. *Pharmacogenet Genomics* 2014;24(10):514-21.
3. Klen J, Dolžan V, Janež A. CYP2C9, KCNJ11 and ABCC8 polymorphisms and response to sulphonylurea treatment in type 2 diabetes patients. *Eur J Clin Pharmacol* 2014;70(4):421-8.
4. Bohanec Grabar P, Leandro-García LJ, Inglada-Pérez L, Logar D, Rodríguez-Antona C, Dolžan V. Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients. *Pharmacogenomics* 2012;13(14):1583-94.
5. Erčulj N, Kovač V, Hmeljak J, Dolžan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. *Ann Oncol* 2012;23(4):961-7.